Seven Eight Capital’s Sage Therapeutics SAGE Stock Holding History

Seven Eight Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-45,494	Closed	-$853K	–	879
2024 Q1	$853K	Buy	45,494 +24,610	+118%	+$568K	0.09%	333
2023 Q4	$453K	Sell	20,884 -21,748	-51%	-$431K	0.05%	440
2023 Q3	$877K	Buy	+42,632	New	+$1.23M	0.1%	273
2021 Q4	–	Sell	-20,397	Closed	-$904K	–	648
2021 Q3	$904K	Buy	20,397 +7,700	+61%	+$353K	0.09%	329
2021 Q2	$721K	Buy	+12,697	New	+$898K	0.1%	345
2020 Q1	–	Sell	-77,074	Closed	-$5.56M	–	672
2019 Q4	$5.56M	Buy	+77,074	New	+$9.48M	0.29%	94
2018 Q1	–	Sell	-2,180	Closed	-$359K	–	517
2017 Q4	$359K	Buy	+2,180	New	+$211K	0.04%	364

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Seven Eight Capital's SAGE Position: Q2 2024 in Review

Seven Eight Capital sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 45,494 shares — an estimated $853K sold.

Seven Eight Capital first reported a position in SAGE in Q4 2017 and held it in 7 quarters. The position peaked at $5.56M in Q4 2019. 194 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

Seven Eight Capital reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
Seven Eight Capital sold 45,494 Sage Therapeutics shares in Q2 2024, an estimated $853K.
Seven Eight Capital first reported a position in Sage Therapeutics in Q4 2017 and held it in 7 quarters.
Seven Eight Capital's Sage Therapeutics position peaked at $5.56M in Q4 2019.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.